Meet the Team
Meet the professionals behind Wahi Pharmaceuticals Incorporation
Our Team
Michael Hakky, MD, is the cofounder of Wahi Pharmaceuticals, Inc. Dr. Hakky is a musculoskeletal radiologist who developed a great interest in basic science research while working at Mass General Hospital.
Michael graduated from Harvard University with a degree in computer science and earned his MD from Virginia Commonwealth University School of Medicine. He has trained at Tufts Medical Center, Lahey Hospital and Medical Center, and Johns Hopkins Hospital
Shahad Al-Khawam is the cofounder of Wahi Pharmaceuticals, Inc and has been interested in herbal and botanical drug research since graduation. Shahad’s investigation established the cornerstone with Dr. Hakky to start Wahi Pharmaceuticals, Inc. Shahad holds a Pharmacy degree from Amman Al-Ahliyya University, Jordan.
Mohammad Al-Khawam is the Chief Financial Officer at Wahi Pharmaceuticals, Inc.
Mohammad holds a Biomedical Engineering degree from Amman Al-Ahliyya University, Jordan, and then received his MBA degree at Kingston University in the UK. Mr. Al-Khawam worked as a Director at Al-Riyadh Co. for Vegetable Oil Industry, and he is a member of the Board of Directors at Stock Trading and Al-Quds Al-Kharasani Companies.
Michael Hakky, MD
is the founder of Wahi Pharmaceuticals, Inc.
Dr. Hakky is a musculoskeletal radiologist who has a great interest in basic science research held at Mass General Hospital.
Michael graduated from Harvard University with computer science and earned his MD degree from Virginia Commonwealth University School of Medicine.
He received his training at Tufts Medical Center and as a Chief radiologist at Lahey Hospital and Medical Center.
Shahad Al-Khawam
is a cofounder of Wahi Pharmaceuticals, Inc and has been interested in herbal and botanical drug research since graduation.
Shahad’s investigation established the cornerstone with Dr. Hakky to find Wahi Pharmaceuticals, Inc. Shahad holds a Pharmacy degree from Amman Al-Ahliyya University, Jordan.
Mohammad Al-Khawam
is the Chief Financial Officer at Wahi Pharmaceuticals, Inc.
Mohammad holds a Biomedical Engineering degree from Amman Al-Ahliyya University, Jordan, and then received his MBA degree at Kingston University in the UK.
Mr. Al-Khawam worked as a Director at Al-Riyadh Co. for Vegetable Oil Industry, and he is a member of the Board of Directors at Stock Trading and Al-Quds Al-Kharasani Companies.
Wahi’s Team of Consultants
Khalid Matalka, Ph.D., is a Chief Scientist in immunology and cancer therapy. Khalid has extensive experience directing and designing preclinical research to move to clinical trials. Khalid worked in Academia and held Dean positions at two different universities and consultant for pharmaceutical companies. Khalid was a Chief Biologist at OncoTherapeutica, Inc. Now, he is a consultant for Startups and Pharmaceutical companies. Khalid’s research led to the development and registration of several drugs and herbal products and has many peer-reviewed publications.
Khalid earned his Ph.D. from Ohio State University and a postdoctoral fellowship from Harvard Medical School.
Fadi Qadan, Ph.D., is a Phytochemist, an expert in developing herbal medicinal and supplemental products. In addition, Fadi is a consultant for several herbal companies and has developed several products registered in the US, Europe, and Middle East markets. Fadi’s has many peer-reviewed publications and a good number of patents.
Fadi received his Ph.D. from the Institute of Pharmaceutical Biology and Phytochemistry, University of Munster, Germany.
Nidal Qinna, Ph.D., is a Pharmacologist and lead experimental scientist and currently the Director of the University of Petra Pharmaceutical Center (UPPC). Dr. Qinna worked as a Deputy Director of the Research and Innovation Center of the Jordanian Pharmaceutical Manufacturing Company (JPM) for several years and currently is a consultant for several pharmaceutical companies. Dr. Qinna has many publications, a few patents, and conducted many regulatory preclinical and toxicological studies.
Nidal earned his Ph.D. from King’s College London, University of London, UK.
Investors
Al Riyadh Investment Companies Group is the main investor of Wahi Pharmaceuticals. Al Riyadh Investment Companies Group established in 1982 and comprises many companies and establishment in various sectors. One of these sectors is public health.
Khalid Matalka, Ph.D.
is a Chief Scientist in immunology and cancer therapy. Khalid has extensive experience directing and designing preclinical research to move to clinical trials. Khalid worked in Academia and held Dean positions at two different universities and consultant for pharmaceutical companies.
Khalid was a Chief Biologist at OncoTherapeutica, Inc. Now, he is a consultant for Startups and Pharmaceutical companies. Khalid’s research led to the development and registration of several products and many research publications.
Khalid earned his Ph.D. from Ohio State University and a postdoctoral fellowship from Harvard Medical School.
Fadi Qadan, Ph.D
is a Phytochemist, an expert in developing herbal medicinal and supplemental products, and has a few patents in his name.
In addition, Fadi is a consultant for several herbal companies and has developed several products registered in the US, Europe, and Middle East markets. Fadi’s research led to the development and registration of several products.
Fadi received his Ph.D. from the Institute of Pharmaceutical Biology and Phytochemistry, University of Munster, Germany.
Nidal Qinna, Ph.D.
is a Pharmacologist and lead experimental scientist and currently the Director of the University of Petra Pharmaceutical Center (UPPC).
Dr. Qinna worked as a Deputy Director of the Research and Innovation Center of the Jordanian Pharmaceutical Manufacturing Company (JPM) for several years and currently is a consultant for several pharmaceutical companies.
Dr. Qinna has several publications, a few patents in his name, and conducted many regulatory preclinical and toxicological studies.
Nidal earned his Ph.D. from King’s College London, University of London, UK.
Our Team
Michael Hakky, MD, is the cofounder of Wahi Pharmaceuticals, Inc. Dr. Hakky is a musculoskeletal radiologist who developed a great interest in basic science research while working at Mass General Hospital.
Michael graduated from Harvard University with a degree in computer science and earned his MD from Virginia Commonwealth University School of Medicine. He has trained at Tufts Medical Center, Lahey Hospital and Medical Center, and Johns Hopkins Hospital
Shahad Al-Khawam is the cofounder of Wahi Pharmaceuticals, Inc and has been interested in herbal and botanical drug research since graduation. Shahad’s investigation established the cornerstone with Dr. Hakky to start Wahi Pharmaceuticals, Inc. Shahad holds a Pharmacy degree from Amman Al-Ahliyya University, Jordan.
Mohammad Al-Khawam is the Chief Financial Officer at Wahi Pharmaceuticals, Inc.
Mohammad holds a Biomedical Engineering degree from Amman Al-Ahliyya University, Jordan, and then received his MBA degree at Kingston University in the UK. Mr. Al-Khawam worked as a Director at Al-Riyadh Co. for Vegetable Oil Industry, and he is a member of the Board of Directors at Stock Trading and Al-Quds Al-Kharasani Companies.
Michael Hakky, MD
is the founder of Wahi Pharmaceuticals, Inc.
Dr. Hakky is a musculoskeletal radiologist who has a great interest in basic science research held at Mass General Hospital.
Michael graduated from Harvard University with computer science and earned his MD degree from Virginia Commonwealth University School of Medicine.
He received his training at Tufts Medical Center and as a Chief radiologist at Lahey Hospital and Medical Center.
Shahad Al-Khawam
is a cofounder of Wahi Pharmaceuticals, Inc and has been interested in herbal and botanical drug research since graduation.
Shahad’s investigation established the cornerstone with Dr. Hakky to find Wahi Pharmaceuticals, Inc. Shahad holds a Pharmacy degree from Amman Al-Ahliyya University, Jordan.
Mohammad Al-Khawam
is the Chief Financial Officer at Wahi Pharmaceuticals, Inc.
Mohammad holds a Biomedical Engineering degree from Amman Al-Ahliyya University, Jordan, and then received his MBA degree at Kingston University in the UK.
Mr. Al-Khawam worked as a Director at Al-Riyadh Co. for Vegetable Oil Industry, and he is a member of the Board of Directors at Stock Trading and Al-Quds Al-Kharasani Companies.
Wahi’s Team of Consultants
Khalid Matalka, Ph.D., is a Chief Scientist in immunology and cancer therapy. Khalid has extensive experience directing and designing preclinical research to move to clinical trials. Khalid worked in Academia and held Dean positions at two different universities and consultant for pharmaceutical companies. Khalid was a Chief Biologist at OncoTherapeutica, Inc. Now, he is a consultant for Startups and Pharmaceutical companies. Khalid’s research led to the development and registration of several drugs and herbal products and has many peer-reviewed publications.
Khalid earned his Ph.D. from Ohio State University and a postdoctoral fellowship from Harvard Medical School.
Fadi Qadan, Ph.D., is a Phytochemist, an expert in developing herbal medicinal and supplemental products. In addition, Fadi is a consultant for several herbal companies and has developed several products registered in the US, Europe, and Middle East markets. Fadi’s has many peer-reviewed publications and a good number of patents.
Fadi received his Ph.D. from the Institute of Pharmaceutical Biology and Phytochemistry, University of Munster, Germany.
Nidal Qinna, Ph.D., is a Pharmacologist and lead experimental scientist and currently the Director of the University of Petra Pharmaceutical Center (UPPC). Dr. Qinna worked as a Deputy Director of the Research and Innovation Center of the Jordanian Pharmaceutical Manufacturing Company (JPM) for several years and currently is a consultant for several pharmaceutical companies. Dr. Qinna has many publications, a few patents, and conducted many regulatory preclinical and toxicological studies.
Nidal earned his Ph.D. from King’s College London, University of London, UK.
Investors
Al Riyadh Investment Companies Group is the main investor of Wahi Pharmaceuticals. Al Riyadh Investment Companies Group established in 1982 and comprises many companies and establishment in various sectors. One of these sectors is public health.
Khalid Matalka, Ph.D.
is a Chief Scientist in immunology and cancer therapy. Khalid has extensive experience directing and designing preclinical research to move to clinical trials. Khalid worked in Academia and held Dean positions at two different universities and consultant for pharmaceutical companies.
Khalid was a Chief Biologist at OncoTherapeutica, Inc. Now, he is a consultant for Startups and Pharmaceutical companies. Khalid’s research led to the development and registration of several products and many research publications.
Khalid earned his Ph.D. from Ohio State University and a postdoctoral fellowship from Harvard Medical School.
Fadi Qadan, Ph.D
is a Phytochemist, an expert in developing herbal medicinal and supplemental products, and has a few patents in his name.
In addition, Fadi is a consultant for several herbal companies and has developed several products registered in the US, Europe, and Middle East markets. Fadi’s research led to the development and registration of several products.
Fadi received his Ph.D. from the Institute of Pharmaceutical Biology and Phytochemistry, University of Munster, Germany.
Nidal Qinna, Ph.D.
is a Pharmacologist and lead experimental scientist and currently the Director of the University of Petra Pharmaceutical Center (UPPC).
Dr. Qinna worked as a Deputy Director of the Research and Innovation Center of the Jordanian Pharmaceutical Manufacturing Company (JPM) for several years and currently is a consultant for several pharmaceutical companies.
Dr. Qinna has several publications, a few patents in his name, and conducted many regulatory preclinical and toxicological studies.
Nidal earned his Ph.D. from King’s College London, University of London, UK.